Sign in
4

Changes in Ownership

Adaptimmune Therapeutics PLC Filed Acc 0001104659-25-015739

Options or other derivatives

  • Chief Executive Officer acquired 8,572,080 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Rawcliffe Adrian Chief Executive Officer 2025-02-20 Grant or award · Option to purchase Ordinary Shares +5,143,248 5,143,248 D
Rawcliffe Adrian Chief Executive Officer 2025-02-20 Grant or award · Option to purchase Ordinary Shares +3,428,832 3,428,832 D
Loading xslF345X05/tm257186-1_4seq1.xml…